Yasui Keisuke, Toshito Toshiyuki, Omachi Chihiro, Hayashi Kensuke, Tanaka Kenichiro, Asai Kumiko, Shimomura Akira, Muramatsu Rie, Hayashi Naoki
Nagoya Proton Therapy Center, Nagoya City West Medical Center, Nagoya, Japan.
School of Health Sciences, Faculty of Radiological Technology, Fujita Health University, Toyoake, Japan.
J Appl Clin Med Phys. 2018 Jan;19(1):132-137. doi: 10.1002/acm2.12231. Epub 2017 Nov 27.
In this study, we evaluate dosimetric advantages of using patient-specific aperture system with intensity-modulated proton therapy (IMPT) for head and neck tumors at the shallow depth. We used four types of patient-specific aperture system (PSAS) to irradiate shallow regions less than 4 g/cm with a sharp lateral penumbra. Ten head and neck IMPT plans with or without aperture were optimized separately with the same 95% prescription dose and same dose constraint for organs at risk (OARs). The plans were compared using dose volume histograms (DVHs), dose distributions, and some dose indexes such as volume receiving 50% of the prescribed dose (V ), mean or maximum dose (D and D ) to the OARs. All examples verified in this study had decreased V and OAR doses. Average, maximum, and minimum relative reductions of V were 15.4%, 38.9%, and 1.0%, respectively. D and D of OARs were decreased by 0.3% to 25.7% and by 1.0% to 46.3%, respectively. The plans with the aperture over more than half of the field showed decreased V or OAR dose by more than 10%. The dosimetric advantage of patient-specific apertures with IMPT was clarified in many cases. The PSAS has some dosimetric advantages for clinical use, and in some cases, it enables to fulfill dose constraints.
在本研究中,我们评估了使用患者特异性孔径系统结合调强质子治疗(IMPT)对头颈部浅表肿瘤的剂量学优势。我们使用了四种类型的患者特异性孔径系统(PSAS)来照射小于4 g/cm的浅表区域,其具有锐利的侧方半影。分别对十个有或无孔径的头颈部IMPT计划进行优化,使其具有相同的95%处方剂量和相同的危及器官(OARs)剂量约束。使用剂量体积直方图(DVHs)、剂量分布以及一些剂量指标(如接受50%处方剂量的体积(V )、OARs的平均或最大剂量(D 和D ))对这些计划进行比较。本研究中验证的所有实例均显示V 和OARs剂量降低。V 的平均、最大和最小相对降低率分别为15.4%、38.9%和1.0%。OARs的D 和D 分别降低了0.3%至25.7%和1.0%至46.3%。孔径覆盖超过一半射野的计划显示V 或OARs剂量降低超过10%。在许多情况下,已明确了患者特异性孔径结合IMPT的剂量学优势。PSAS在临床应用中具有一些剂量学优势,在某些情况下,它能够满足剂量约束。